Skip to content

Robotic-assisted Left Hemicolectomy for Left Colon Cancer

Robotic-assisted Left Hemicolectomy for Left Colon Cancer With a Medial-to-lateral Approach Orientated by AMA or AMV

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03696472
Acronym
RALH
Enrollment
2
Registered
2018-10-04
Start date
2018-12-31
Completion date
2020-12-31
Last updated
2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer

Brief summary

The main goal of this study is to clarify if Robotic-assisted surgery could become the standard approach in patients undergoing left colonic resection. Patient candidates to left colonic resection were randomly assigned to Robotic(RAL) or laparoscopic(LL) approach. The surgical staff who were not involved in the study registered 30-day postoperative morbidity. Cost-benefit analysis was based on hospital days. Long-term morbidity, quality of life, and 5-year survival have also been evaluated

Detailed description

Robotic-assisted Left Hemicolectomy as advantages on showing the inferior mesenteric artery (IMA), protection of autonomic nerve compare to laparoscopic approach. Our experience found that operational flexibility was advantage without surgeon's position exchange.

Interventions

robotic assisted surgery was benefit to operation

PROCEDURElaparoscopic

conventional laparoscopic surgery

Sponsors

Southwest Hospital, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Colon cancer adenocarcinoma The tumor located between the descending colon and the right 1/3 of transverse colon Tumors T3,Т4а,b N0-2 Tolerance of chemotherapy ECOG 0-2

Exclusion criteria

With distant metastases Tumors T1-2 Complications of tumor Women during Pregnancy

Design outcomes

Primary

MeasureTime frame
5-years overall survival rate5 years

Secondary

MeasureTime frame
Anastomosis leakage rate6 months
Operation Time1 day
Blood loss during operation1 day
Short-term morbidity rate30 days
C-reaction protein level7 days
Recovery time after surgery60 days
Complication incident rate of surgery1 day

Countries

China

Contacts

Primary ContactLi Chuan, M.D
lee_tran@126.com+862368754167
Backup ContactTang Bo, M.D
tangtbo@sina.cn+86-18323479228

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026